ARROWHEAD PHARMACEUTICALS, INC. Operating Cash Flow
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Operating Cash Flow of -$79.55 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$177.47M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $84.44M, a 81.65% decline year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $13.48M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $20.49M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $179.55M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$462.85M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$153.89M.
- ARROWHEAD PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$136.13M, a 179.46% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$177.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | -$93.03M derived: sum of 2 quarters · filed 2026-08-04 | -$79.55M 10-Q · filed 2026-08-04 | -$59.05M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $84.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | $97.92M 10-Q · filed 2026-05-07 | $118.41M derived: sum of 3 quarters · filed 2026-05-07 | -$36.31M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $13.48M 10-Q · filed 2026-02-05 | $33.97M derived: sum of 2 quarters · filed 2026-02-05 | -$120.75M derived: sum of 3 quarters · filed 2026-08-04 | $339.31M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-09-30 | $20.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$134.23M derived: sum of 2 quarters · filed 2026-08-04 | $325.82M derived: sum of 3 quarters · filed 2026-08-04 | $179.55M 10-K · filed 2025-11-25 | ||||
| 2025-06-30 | -$154.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-04 | $305.33M derived: sum of 2 quarters · filed 2026-08-04 | $159.06M 10-Q · filed 2026-08-04 | $21.84M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $460.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-07 | $313.78M 10-Q · filed 2026-05-07 | $176.56M derived: sum of 3 quarters · filed 2026-05-07 | $61.15M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | -$146.27M 10-Q · filed 2026-02-05 | -$283.49M derived: sum of 2 quarters · filed 2026-02-05 | -$398.91M derived: sum of 3 quarters · filed 2026-02-05 | -$491.28M derived: sum of 4 quarters · filed 2026-02-05 | ||||
| 2024-09-30 | -$137.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$252.63M derived: sum of 2 quarters · filed 2025-11-25 | -$345.01M derived: sum of 3 quarters · filed 2025-11-25 | -$462.85M 10-K · filed 2025-11-25 | ||||
| 2024-06-30 | -$115.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-07 | -$207.79M derived: sum of 2 quarters · filed 2025-08-07 | -$325.63M 10-Q · filed 2025-08-07 | -$351.56M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2024-03-31 | -$92.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-12 | -$210.22M 10-Q · filed 2025-05-12 | -$236.14M derived: sum of 3 quarters · filed 2025-11-25 | -$256.92M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2023-12-31 | -$117.84M 10-Q · filed 2025-02-10 | -$143.77M derived: sum of 2 quarters · filed 2025-11-25 | -$164.54M derived: sum of 3 quarters · filed 2025-11-25 | -$196.21M derived: sum of 4 quarters · filed 2025-11-25 | ||||
| 2023-09-30 | -$25.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | -$46.70M derived: sum of 2 quarters · filed 2025-11-25 | -$78.37M derived: sum of 3 quarters · filed 2025-11-25 | -$153.89M 10-K · filed 2025-11-25 | ||||
| 2023-06-30 | -$20.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-08 | -$52.45M derived: sum of 2 quarters · filed 2024-08-08 | -$127.96M 10-Q · filed 2024-08-08 | -$128.63M 10-Q · filed 2023-08-07 | -$196.70M derived: sum of 4 quarters · filed 2024-11-26 | |||
| 2023-03-31 | -$31.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | -$107.19M 10-Q · filed 2024-05-09 | -$175.92M derived: sum of 3 quarters · filed 2024-11-26 | -$244.74M derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2022-12-31 | -$75.52M 10-Q · filed 2024-02-06 | -$144.25M derived: sum of 2 quarters · filed 2024-11-26 | -$213.07M derived: sum of 3 quarters · filed 2024-11-26 | -$150.34M derived: sum of 4 quarters · filed 2024-11-26 | ||||
| 2022-09-30 | -$68.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-26 | -$137.55M derived: sum of 2 quarters · filed 2024-11-26 | -$74.82M derived: sum of 3 quarters · filed 2024-11-26 | -$136.13M 10-K · filed 2024-11-26 | ||||
| 2022-06-30 | -$68.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | -$6.09M derived: sum of 2 quarters · filed 2023-08-07 | -$67.39M 10-Q · filed 2023-08-07 | -$67.46M 10-Q · filed 2022-08-04 | -$91.42M derived: sum of 4 quarters · filed 2023-11-29 | |||
| 2022-03-31 | $62.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-02 | $1.42M 10-Q · filed 2023-05-02 | $1.38M 10-Q · filed 2022-05-10 | -$22.61M derived: sum of 3 quarters · filed 2023-11-29 | -$52.22M derived: sum of 4 quarters · filed 2023-11-29 | |||
| 2021-12-31 | -$61.31M 10-Q · filed 2023-02-06 | -$61.35M 10-Q · filed 2022-02-02 | -$85.34M derived: sum of 2 quarters · filed 2023-11-29 | -$114.95M derived: sum of 3 quarters · filed 2023-11-29 | $148.93M derived: sum of 4 quarters · filed 2023-11-29 | |||
| 2021-09-30 | -$24.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | -$53.64M derived: sum of 2 quarters · filed 2023-11-29 | $210.23M derived: sum of 3 quarters · filed 2023-11-29 | $171.31M 10-K · filed 2023-11-29 | $171.22M 10-K · filed 2021-11-22 | |||
| 2021-06-30 | -$29.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-04 | $234.26M derived: sum of 2 quarters · filed 2022-08-04 | $195.34M 10-Q · filed 2022-08-04 | $184.08M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2021-03-31 | $263.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-10 | $224.95M 10-Q · filed 2022-05-10 | $213.69M derived: sum of 3 quarters · filed 2022-11-28 | $180.26M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2020-12-31 | -$38.92M 10-Q · filed 2022-02-02 | -$50.18M derived: sum of 2 quarters · filed 2022-11-28 | -$83.61M derived: sum of 3 quarters · filed 2022-11-28 | -$111.19M derived: sum of 4 quarters · filed 2022-11-28 | ||||
| 2020-09-30 | -$11.26M derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-28 | -$44.69M derived: sum of 2 quarters · filed 2022-11-28 | -$72.27M derived: sum of 3 quarters · filed 2022-11-28 | -$95.80M 10-K · filed 2022-11-28 | -$95.39M 10-K · filed 2020-11-23 | |||
| 2020-06-30 | -$33.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-08-05 | -$61.01M derived: sum of 2 quarters · filed 2021-08-05 | -$84.54M 10-Q · filed 2021-08-05 | -$84.54M 10-Q · filed 2020-08-05 | -$70.73M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2020-03-31 | -$27.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-05-04 | -$51.12M 10-Q · filed 2021-05-04 | -$51.11M 10-Q · filed 2020-05-07 | -$37.31M derived: sum of 3 quarters · filed 2021-11-22 | -$26.78M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2019-12-31 | -$23.53M 10-Q · filed 2021-02-04 | -$23.53M 10-Q · filed 2020-02-05 | -$9.72M derived: sum of 2 quarters · filed 2021-11-22 | $806.75K derived: sum of 3 quarters · filed 2021-11-22 | -$18.78M derived: sum of 4 quarters · filed 2021-11-22 | |||
| 2019-09-30 | $13.81M derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-22 | $24.34M derived: sum of 2 quarters · filed 2021-11-22 | $4.75M derived: sum of 3 quarters · filed 2021-11-22 | $173.03M 10-K · filed 2021-11-22 | $173.03M 10-K · filed 2019-11-25 | |||
| 2019-06-30 | $10.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-05 | -$9.06M derived: sum of 2 quarters · filed 2020-08-05 | $159.23M 10-Q · filed 2020-08-05 | $156.54M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2019-03-31 | -$19.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-07 | $148.70M 10-Q · filed 2020-05-07 | $146.02M derived: sum of 3 quarters · filed 2020-11-23 | $131.61M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2018-12-31 | $168.28M 10-Q · filed 2020-02-05 | $165.60M derived: sum of 2 quarters · filed 2020-11-23 | $151.20M derived: sum of 3 quarters · filed 2020-11-23 | $135.75M derived: sum of 4 quarters · filed 2020-11-23 | ||||
| 2018-09-30 | -$2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-23 | -$17.09M derived: sum of 2 quarters · filed 2020-11-23 | -$32.53M derived: sum of 3 quarters · filed 2020-11-23 | -$47.22M 10-K · filed 2020-11-23 | ||||
| 2018-06-30 | -$14.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-05 | -$29.85M derived: sum of 2 quarters · filed 2019-08-05 | -$44.54M 10-Q · filed 2019-08-05 | -$53.75M derived: sum of 4 quarters · filed 2019-11-25 | ||||
| 2018-03-31 | -$15.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-08 | -$30.13M 10-Q · filed 2019-05-08 | -$39.34M derived: sum of 3 quarters · filed 2019-11-25 | |||||
| 2017-12-31 | -$14.69M 10-Q · filed 2019-02-07 | -$23.89M derived: sum of 2 quarters · filed 2019-11-25 | ||||||
| 2017-09-30 | -$9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-25 | -$23.94M 10-K · filed 2019-11-25 | ||||||
| 2017-06-30 | -$14.74M 10-Q · filed 2018-08-07 | |||||||
| 2016-09-30 | -$64.43M 10-K · filed 2018-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |